Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: pha-793887, roniciclib, at-7519 +1 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 16528
Sealed predictions
- CDK16 in dopamine neurons, braak-0.09 (p 0.815) → +0.04 (p 0.924)receipt 16536
Swarm cases
receipt 16536: CDK16 in dopamine neurons, braak
- power
- full sample -0.10 (p 0.690, n 18), 95% CI -0.54 to +0.38. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.16 (p 0.515, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.15 (p 0.555, n 18). could be the mix.
- skeptic
- leave-one-out range -0.24 to +0.00, sign flips 1; without severely affected donors -0.10 (p 0.690, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CDK16 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts